[{"orgOrder":0,"company":"Berlin Cures","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Rovunaptabin","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Berlin Cures","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Berlin Cures \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Berlin Cures \/ Inapplicable"},{"orgOrder":0,"company":"Berlin Cures","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Rovunaptabin","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Berlin Cures","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Berlin Cures \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Berlin Cures \/ Inapplicable"},{"orgOrder":0,"company":"Berlin Cures","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Rovunaptabin","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Berlin Cures","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Berlin Cures \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Berlin Cures \/ Inapplicable"},{"orgOrder":0,"company":"Berlin Cures","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BC007","moa":"Thrombin","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Berlin Cures","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Berlin Cures \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Berlin Cures \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Berlin Cures

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Vitafoods
                          Not Confirmed
                          Vitafoods
                          Not Confirmed

                          Details : BC 007 (rovunaptabin) is a novel therapeutic candidate using DNA-based aptamers to target and neutralize functional autoantibodies against G-protein coupled receptors for Long COVID.

                          Product Name : Undisclosed

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          April 23, 2024

                          Lead Product(s) : Rovunaptabin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Vitafoods
                          Not Confirmed
                          Vitafoods
                          Not Confirmed

                          Details : BC 007 is a DNA-based aptamer designed to specifically target and neutralize functional autoantibodies (fAABs) directed against G-protein coupled receptors. It is being evaluated for Long Covid.

                          Product Name : Undisclosed

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          April 03, 2024

                          Lead Product(s) : Rovunaptabin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Vitafoods
                          Not Confirmed
                          Vitafoods
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          June 20, 2023

                          Lead Product(s) : BC007

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Vitafoods
                          Not Confirmed
                          Vitafoods
                          Not Confirmed

                          Details : Berlin Cures Holding AG is evaluating BC 007, a β1-adrenoceptor autoantibody neutralizing ssDNA product, for the treatment of COVID-19. BC 007 consists of a synthetically produced short and unmodified aptamer, which is able to bind to the spike protein ...

                          Product Name : Undisclosed

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          June 24, 2020

                          Lead Product(s) : Rovunaptabin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Vitafoods
                          Not Confirmed
                          Vitafoods
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          December 10, 2019

                          Lead Product(s) : BC 007

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Vitafoods
                          Not Confirmed
                          Vitafoods
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          November 04, 2016

                          Lead Product(s) : BC 007

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank